Sign in Subscribe

crc-research

A collection of 723 issues

CRC Research Update — July 12, 2026

Today's colorectal cancer research highlights

Y-linked RNA helicase DDX3Y may act as tumor suppressor in male colorectal cancer

Skip to content The CRC Digest Y-linked RNA helicase DDX3Y may act as tumor suppressor in male colorectal cancer First evidence shows DDX3Y, a Y chromosome gene, is downregulated in male CRC tumors and may help explain why men experience higher incidence, metastasis, and mortality rates. (Biochemical Genetics) This content

Ohio study compares risk factors between early-onset and late-onset colorectal cancer

Skip to content The CRC Digest Ohio study compares risk factors between early-onset and late-onset colorectal cancer Researchers examined demographic, lifestyle, and clinical risk factors that differ between patients diagnosed before age 50 versus those diagnosed at 50 or older. (Cancer Causes & Control) This content is informational only and

Prolonged diagnostic delays linked to advanced-stage presentation in early-onset CRC in Mexico

Skip to content The CRC Digest Prolonged diagnostic delays linked to advanced-stage presentation in early-onset CRC in Mexico (Cureus) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The CRC Digest — crcdigest.com

CRC Research Finding

Skip to content The CRC Digest ◇ Systematic review examines Fusobacterium nucleatum as predictor of treatment response A systematic review evaluated whether Fusobacterium nucleatum, a bacterium implicated in CRC progression and immune modulation, can predict treatment response, though its role as a biomarker remains unclear. (Cancer Treatment Reviews) This content is

This Week in CRC Research — July 12, 2026

Weekly colorectal cancer research intelligence

Metronomic chemotherapy plus regorafenib tested in treatment-resistant metastatic colorectal cancer

Skip to content The CRC Digest ▸ TREATMENT Metronomic chemotherapy plus regorafenib tested in treatment-resistant metastatic colorectal cancer — ESMO Gastrointestinal Oncology The REPROGRAM-01 single-arm phase II trial tested regorafenib combined with metronomic capecitabine, cyclophosphamide, and aspirin in refractory metastatic colorectal cancer. This approach aims to improve outcomes in heavily pre-treated patients

Testing immunotherapy combination in MSS metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Testing immunotherapy combination in MSS metastatic colorectal cancer — Clinical Colorectal Cancer A Phase II study of pembrolizumab plus capecitabine and bevacizumab for microsatellite stable/mismatch repair-proficient metastatic colorectal cancer. Most colorectal cancers are MSS/pMMR and don't respond well to

Encorafenib and cetuximab re-challenge combined with nivolumab in BRAF-mutated colorectal cancer

Skip to content The CRC Digest ▸ TREATMENT Encorafenib and cetuximab re-challenge combined with nivolumab in BRAF-mutated colorectal cancer — Clinical Colorectal Cancer A case report from the AGMT mCRC Registry documented successful encorafenib and cetuximab re-challenge combined with nivolumab in BRAF V600E mutated, mismatch-repair-proficient metastatic colorectal cancer. If you have BRAF

Adding immunotherapy to chemotherapy before surgery in stage III colon cancer

Skip to content The CRC Digest ◆ TRIAL DATA Adding immunotherapy to chemotherapy before surgery in stage III colon cancer — Clinical Colorectal Cancer The AZUR-4 trial is a Phase 2, open label, randomized study of neoadjuvant dostarlimab plus CAPEOX versus CAPEOX in previously untreated T4N0 or stage III mismatch repair proficient/